Gilead Sciences Inc (GILD.OQ)
62.00USD
1 Aug 2013
$0.55 (+0.89%)
$61.45
$62.08
$62.18
$60.98
2,273,703
3,644,975
$64.03
$26.75
About
Overall
| Beta: | 0.55 |
| Market Cap (Mil.): | $93,656.85 |
| Shares Outstanding (Mil.): | 1,525.36 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| GILD.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 40.73 | 47.13 | 37.76 |
| EPS (TTM): | 1.51 | -- | -- |
| ROI: | 17.60 | -2.58 | 18.76 |
| ROE: | 30.32 | -2.66 | 19.59 |
EU regulators back Novartis inhaler, Gilead HIV drug
LONDON, July 26 - European regulators on Friday recommended approval of a new once-daily inhaler for lung disease from Novartis and an HIV medicine from Gilead Sciences.
Gilead profit rises, shares jump on Vertex hepatitis setback
- Shares of biotechnology company Gilead Sciences Inc jumped more than 5 percent late Thursday after rival Vertex Pharmaceuticals Inc announced a setback in development of its experimental hepatitis C drug.
UPDATE 2-Gilead profit rises, shares jump on Vertex hepatitis setback
* Gilead is biggest maker of branded drugs to treat HIV (Adds company and analyst comments, updates share price)
Gilead profit meets Wall St forecast, sales rise 14 pct
July 25 - Gilead Sciences Inc on Thursday said its quarterly profit rose nearly 9 percent, in line with Wall Street estimates, as sales, including of its flagship HIV drugs, increased 14 percent.
FDA grants priority review status to Gilead's hepatitis C drug
June 7 - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.
Experimental Gilead drug effective in early-stage leukemia trial
- An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
Experimental Gilead drug effective in early-stage leukemia trial
May 15 - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
Gilead profit rises, but sales of older HIV drugs dip
- Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.
UPDATE 2-Gilead profit rises, but sales of older HIV drugs dip
May 2 - Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.
CORRECTED-Gilead profit rises 63 pct, sales of older HIV drugs dip
(Corrects 3rd paragraph to show Complera sales rose 184 percent, not 10 percent; shows that sales of Stribild totaled $92.1 million, with no prior year comparison, not that they rose 184 percent)
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| Abbott Laboratories (ABT.N) | $36.84 | +0.21 |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
| Bristol Myers Squibb Co. (BMY.N) | $43.99 | +0.75 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
| Shire PLC (SHP.L) | 2,440.00p | +38.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

